Interaction of a novel platinum drug with bovine serum albumin: FTIR and UV-Vis spectroscopy analysis

2015-01-01
Korkmaz, Filiz
Altunöz Erdoğan, Deniz
Ozalp-Yaman, Seniz
Show full item record
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
110
views
0
downloads
Platinum complexes have proven to be very effective in cancer treatment. However, severe side effects of these drugs have lead scientists to pursue new platinum complex derivatives. A novel blue platinum compound, called Platinum-Blue (Pt-Blue), is one of the promising candidate platinum compounds to be used for tumor treatment. In this study, the interaction of Pt-Blue with bovine serum albumin (BSA) has been investigated using UV-Vis and FTIR spectroscopy. One of the findings is that the drug-protein interaction type depends on the drug concentration. Though Pt-Blue is attached to the surface of BSA at high concentrations, it interacts with a hydrophobic region of the protein at low concentrations with a binding constant of 1.93 x 10(5) M-1. Spectroscopic results indicate the hydrophobic docking position to be around Trp 213 in domain II, which is surrounded by a number of Asp and Glu. During this interaction, helices such as helix-10, helix-18, helix-19 and helix-24 change orientation and/or partially unfold to make room for the compound. Binding constants at high and low concentrations of Pt-Blue are determined using UV-Vis spectroscopy, which are found to be comparable to cisplatin. FTIR spectroscopy also reveals that the interaction between Pt-Blue and BSA is noncovalent, which makes the candidate drug favorable because it is available for DNA binding while being carried by albumin.
Transform infrared-spectroscopy, Protein secondary structure, Membrane-proteins, IR spectroscopy, Phase-I, Binding, Peptides, Complexes, Blues, Methodology
https://hdl.handle.net/11511/38896
NEW JOURNAL OF CHEMISTRY
Department of Chemistry, Article

Suggestions

Nanoparticles Based Drug Delivery Systems to Overcome Multidrug Resistance in Cancer The Role of Membrane Lipids Proteins and Carbohydrates
Özlüer, Özlem; Yalçın Azarkan, Serap; Gündüz, Ufuk (null; 2016-09-28)
Multidrug resistance (MDR) is a major problem in success of cancer chemotherapy on tumor cell growth, limits the prolonged and effective use of chemotherapy. The use of nanomaterial based drug carriers in cancer treatment offers exciting opportunities to enhance delivery of therapeutics to the tumor site (1). This is also known as targeted drug delivery providing differential distribution of drugs to the tumor site while significantly reducing the overall toxicity. Here, we critically discuss the role of th...
Reversal of breast cancer resistance protein mediated multidrug resistance in MCF7 breast adenocarcinoma cell line
Urfalı, Çağrı; Gündüz, Ufuk; Department of Biology (2011)
Resistance to various chemotherapeutic agents is a major problem in success of cancer chemotherapy. One of the primary reasons of development of multidrug resistance (MDR) is the overexpression of ATP binding cassette (ABC) transporter proteins. Breast cancer resistance protein (BCRP) belongs to ABC transporter family and encoded by ABCG2 gene. BCRP is mainly expressed in MDR1 (P-glycoprotein) lacking breast cancer cells. Overexpression of BCRP leads to efflux of chemotherapeutic agents at higher rates, the...
The role of 15-LOX-1 in resistance to chemotherapeutics
Kazan, Hasan Hüseyin; Gündüz, Ufuk; Department of Biology (2020)
Chemotherapy is one of the best options to treat cancer. However, drug resistance can limit the efficacy of chemotherapeutics. There have been several reasons for the cancer drug resistance including the export of the drug from cells, inactivation of drugs by enzymatic processes, mutations that limit the binding of the drugs to the target proteins, resistance to cell death mechanism by cellular manipulations and reorganization of the cell membrane. 15-Lipoxygenase-1 (15-LOX-1) is a member of the lipoxygenas...
Leveraging the Molecular Signatures of Cancer for Dynamic Network Modeling
Tunçbağ , Nurcan; Ayar , Enes Sefa (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10)
Molecular heterogeneity and resistance to the treatment are among the obstacles in developing treatment strategies in cancer. Therefore, transforming patient-specific molecular data into clinically interpretable knowledge is fundamental in personalized medicine. However, not all molecular alterations drive cancer. The distinction of drivers from latent drivers and passengers, their cooperativity and exclusivity, and the temporal order of accumulation of molecular alterations is a crucial yet daunting, unsol...
Cell-surface interactions in a breast cancer model
Antmen, Ezgi; Hasırcı, Vasıf Nejat; Demirci, Utkan; Department of Biotechnology (2017)
Breast cancer, is one of the most commonly diagnosed cancers, has a high mortality rate. One in every eight women (12.3%) develops breast cancer at some stage of their lives and this is the cause of about 15% of cancer deaths in women and 3% of total deaths. It is therefore important to study the behavior of breast cancer cells. Measurement of the mechanical properties of cancer cells leads to new insights such as that cancer cells are softer than healthy cells. Also, metastatic cancer cells were found to b...
Citation Formats
F. Korkmaz, D. Altunöz Erdoğan, and S. Ozalp-Yaman, “Interaction of a novel platinum drug with bovine serum albumin: FTIR and UV-Vis spectroscopy analysis,” NEW JOURNAL OF CHEMISTRY, pp. 5676–5685, 2015, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/38896.
METU IIS - Integrated Information Service open@metu.edu.tr